Tiger Pharmaceutical (03347.HK) plans to invest 200 million yuan to participate in the biopharmaceutical industry fund, laying out the track of innovative drugs and high-end equipment.

Zhixin Finance APP news, Taige Medicine (03347.HK) announced that the company intends to participate in the investment of Shanghai Sansheng Medicine Private Equity Investment Fund Partnership Enterprise (Limited Partnership) through Hangzhou Taige Equity Investment Partnership Enterprise (Limited Partnership) (hereinafter referred to as "the investment subject of this investment"). The first phase of the partnership enterprise intends to subscribe for a total capital contribution of 950 million yuan. The investment subject of this investment will subscribe for 200 million yuan with its own funds as a limited partner (LP) of the partnership enterprise.